keyword
MENU ▼
Read by QxMD icon Read
search

Androgen deprivation therapy

keyword
https://www.readbyqxmd.com/read/29350549/abiraterone-acetate-and-its-use-in-the-treatment-of-metastatic-prostate-cancer-a-review
#1
Orazio Caffo, Antonello Veccia, Stefania Kinspergher, Francesca Maines
Abiraterone acetate, which targets enzymatic complexes playing a central role in steroidogenesis, demonstrated to increase survival significantly in both chemo-naive and docetaxel pretreated, becoming one of the drugs of choice for metastatic castration-resistant prostate cancer. More recently, this agent in combination to androgen deprivation therapy demonstrated to be efficacious also in metastatic castration-sensitive prostate cancer. The present review is aimed to outline the clinical development of abiraterone acetate, the pivotal trials which led to its approval for the clinical practice, new evidence about its efficacy in metastatic castration-sensitive prostate cancer, its place in the therapeutic landscape of prostate cancer and future directions of development...
January 19, 2018: Future Oncology
https://www.readbyqxmd.com/read/29345442/lung-uptake-of-fluorine-18-fluoroethyl-choline-pet-ct-in-patients-with-prostate-cancer
#2
Daniele A Pizzuto, Salvatore Annunziata, Francesco P Ieria, Carmelo Caldarella, Maria A Isgrò, Valerio Lanni, Gaia Bencivenga, Vittoria Rufini, Alessandro Giordano
BACKGROUND: Metastatic spreading to the lungs is a negative prognostic factor in patients with prostate cancer (PC). Aim of our study was to assess the prevalence of lung PC metastases in patients with fluorine-18 fluoroethyl-choline (F-18-FECh) PET-CT positive lung lesions and the role of Gleason Score (GS) and common biochemical markers in predicting metastatic spreading to the lungs. METHODS: We retrospectively evaluated the scans of 1283 patients ongoing (F-18-FECh) PET-CT for PC between May 2010 and July 2014...
January 17, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29345000/cell-death-under-epithelial-mesenchymal-transition-control-in-prostate-cancer-therapeutic-response
#3
REVIEW
Diane Begemann, Harry Anastos, Natasha Kyprianou
Prostate cancer is a widespread problem among men, with >160 000 new cases in 2017 alone. Androgen deprivation therapy is commonly used in prostate cancer treatment to block androgens required for cancer growth, but disease relapse after androgen deprivation therapy is both common and severe. Changes in androgen receptor signaling from androgen deprivation therapy have been linked to therapeutic resistance and tumor progression. Resistant cells can become reprogrammed to undergo epithelial-mesenchymal transition, a phenotypic switch from benign, epithelial cells to a mobile cell with mesenchymal traits...
January 17, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29338083/androgen-deprivation-therapy-dementia-and-cognitive-dysfunction-in-men-with-prostate-cancer-how-much-smoke-and-how-much-fire
#4
REVIEW
Deaglan J McHugh, James C Root, Christian J Nelson, Michael J Morris
Androgen-deprivation therapy (ADT) remains the cornerstone of management for patients with metastatic prostate cancer. Although the toxicities of ADT are well established, there is increasing controversy surrounding the association between cognitive dysfunction and the receipt of ADT, with some evidence suggesting an increased risk of dementia. The authors conducted a literature search to identify pertinent clinical studies in this field. This general review outlines the key findings and discusses the relative strengths and weaknesses when drawing conclusions about the risk of cognitive dysfunction or dementia with ADT use...
January 16, 2018: Cancer
https://www.readbyqxmd.com/read/29338073/impact-of-time-to-testosterone-rebound-and-comorbidity-on-the-risk-of-cause-specific-mortality-in-men-with-unfavorable-risk-prostate-cancer
#5
Susan G R McDuff, Ming-Hui Chen, Andrew A Renshaw, Marian J Loffredo, Philip W Kantoff, Anthony V D'Amico
BACKGROUND: Herein, the authors evaluated how the time to testosterone rebound (TTR) after radiotherapy (RT) and 6 months of androgen deprivation therapy (ADT) impacted the risk of prostate cancer-specific mortality (PCSM) and cardiovascular-specific mortality (CVM) among men with varying comorbidity extent. METHODS: Between 1995 and 2001, a total of 206 men who were randomized to receive RT either alone or with 6 months of ADT for unfavorable-risk PC and who had a comorbidity score assigned using the Adult Comorbidity Evaluation 27 metric comprised the study cohort...
January 16, 2018: Cancer
https://www.readbyqxmd.com/read/29337395/testosterone-suppression-with-luteinizing-hormone-releasing-hormone-lhrh-agonists-in-patients-receiving-radiotherapy-for-prostate-cancer
#6
Derek Wilke, Nikhilesh Patil, Helmut Hollenhorst, David Bowes, Robert Rutledge, Casely Ago
OBJECTIVES: To characterize the probability of testosterone escape during a course of radiotherapy and androgen deprivation (ADT) in patients with prostate cancer, and examine predictors of testosterone escape, the prostate specific antigen (PSA) levels during testosterone escape, and the impact of testosterone escape on outcome. PATIENTS AND METHODS: To participate in the database review, necessary data included: (i) type of luteinizing hormone-releasing hormone agonist (LHRHa) administered, date of initiation, and date of cessation or duration of therapy, (ii) radiotherapy information (start date and dose) with at least 6 months of follow-up after radiotherapy, (iii) had to have radiotherapy to the prostate or prostate bed, and (iv) had to have a least one serum testosterone and PSA measurement...
January 16, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29336109/moderate-hypofractionation-for-prostate-cancer-a-user-s-guide
#7
REVIEW
David I Pryor, Sandra L Turner, Keen Hun Tai, Colin Tang, Giuseppe Sasso, Marcus Dreosti, Henry H Woo, Lee Wilton, Jarad M Martin
Three large randomised controlled trials have been published in the last year demonstrating the non-inferiority of moderate hypofractionation compared to conventional fractionation for localised prostate cancer with respect to both disease control and late toxicity at 5 years. Furthermore, no clinically significant differences in patient-reported outcomes have emerged. More mature follow-up data are now also available from phase 2 studies confirming that moderate hypofractionation is associated with low rates of significant toxicity at 10 years...
January 16, 2018: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29333925/androgen-receptor-independent-prostate-cancer-an-emerging-clinical-entity
#8
Ilyas Sahin, Anthony E Mega, Benedito A Carneiro
Androgen deprivation therapy remains the backbone of prostate cancer treatment given its pivotal role in the pathogenesis of prostate cancer. The growing knowledge of androgen receptor-independent (i.e. AR-null) prostate cancer cells, however, might advance the treatment paradigm of prostate cancer particularly in castration resistance stage by targeting these pathways. Here, we examined the results of two recent studies, published in Cancer Cell by Bluemn and Shukla et al., and possible clinical impact of these studies in the near future in castration resistance prostate cancer...
January 15, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29333510/factors-associated-with-testosterone-recovery-after-androgen-deprivation-therapy-in-patients-with-prostate-cancer
#9
Wook Nam, Se Young Choi, Sang Jun Yoo, Jeman Ryu, Jaehoon Lee, Yoon Soo Kyung, Jae Hyeon Han, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
Purpose: We investigated factors affecting testosterone recovery after androgen deprivation therapy (ADT) withdrawal in patients with prostate cancer. Materials and Methods: The medical records of patients who underwent radical prostatectomy with ADT were retrospectively reviewed. In all, 221 patients were included in the analysis. Testosterone recovery was defined as supra-castration (SC) (testosterone levels in serum >50 ng/dL) or out of hypogonadism (OH) (>300 ng/dL) after ADT withdrawal...
January 2018: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/29332354/inhibition-of-telomerase-potentiates-enzalutamide-efficiency-of-androgen-sensitive-human-prostate-cancer-cells
#10
Karaca Kaan Gecgel, Mustafa Muduroglu, Suat Erdogan
PURPOSE: Androgen deprivation therapy (ADT) is one of the main strategies to treat prostate cancer (PCa) at various stages of its development. Androgen receptor (AR) antagonists such as enzalutamide are mainstay treatments for castration-sensitive prostate cancer. Though, a majority of patients initially respond to ADT, most will eventually progress to castrate-resistant, due to the development of different mutations on the AR. PCa cells express high telomerase activity, and there is a correlation between the total activity of telomerase and the Gleason score...
November 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29331381/clinical-outcomes-of-first-line-abiraterone-acetate-or-enzalutamide-for-metastatic-castration-resistant-prostate-cancer-after-androgen-deprivation-therapy%C3%A2-docetaxel-or-adt-alone-for-metastatic-hormone-sensitive-prostate-cancer
#11
Edoardo Francini, Steven Yip, Shubidito Ahmed, Haocheng Li, Luke Ardolino, Carolyn P Evan, Marina Kaymakcalan, Grace K Shaw, Philip W Kantoff, Mary-Ellen Taplin, Nimira S Alimohamed, Anthony M Joshua, Daniel Y C Heng, Christopher J Sweeney
BACKGROUND: The CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abiraterone acetate (AA) and enzalutamide (E) are the most commonly used first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), we aimed to assess whether they maintained their efficacy after ADT+D versus ADT alone...
December 27, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29326030/patient-reported-outcomes-following-abiraterone-acetate-plus-prednisone-added-to-androgen-deprivation-therapy-in-patients-with-newly-diagnosed-metastatic-castration-naive-prostate-cancer-latitude-an-international-randomised-phase-3-trial
#12
Kim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, Gaetano Facchini, Henrik Suttman, Nobuaki Matsubara, Zhangqun Ye, Bhumsuk Keam, Ronaldo Damião, Tracy Li, Kelly McQuarrie, Bin Jia, Peter De Porre, Jason Martin, Mary B Todd, Karim Fizazi
BACKGROUND: In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study...
January 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29323427/duration-of-androgen-deprivation-therapy-and-nadir-of-testosterone-at-20-ng-dl-predict-testosterone-recovery-to-supracastrate-level-in-prostate-cancer-patients-who-received-external-beam-radiotherapy
#13
Akinori Takei, Shinichi Sakamoto, Ken Wakai, Takaaki Tamura, Yusuke Imamura, Minhui Xu, Maihulan Maimaiti, Koji Kawamura, Takashi Imamoto, Akira Komiya, Koichiro Akakura, Tomohiko Ichikawa
OBJECTIVES: To determine the predictors of testosterone recovery after termination of androgen deprivation therapy in high/intermediate-risk prostate cancer patients receiving external beam radiation therapy with neoadjuvant and adjuvant androgen deprivation therapy. METHODS: A total of 82 patients who underwent external beam radiation therapy with androgen deprivation therapy for prostate cancer were retrospectively analyzed. Serum testosterone levels after androgen deprivation therapy terminations were studied...
January 11, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29320570/image-guided-whole-pelvic-intensity-modulated-radiotherapy-for-biochemical-recurrence-following-radical-prostatectomy-in-high-risk-prostate-cancer-patients
#14
Sang Jun Byun, Young Seok Kim, Hanjong Ahn, Choung-Soo Kim
BACKGROUND: The optimal field size of salvage radiotherapy (SRT) for biochemical recurrence, particularly for patients with high-risk prostate cancer, remains undefined. This retrospective analysis was performed to investigate oncological outcomes as well as treatment-related toxicity following salvage intensity-modulated radiotherapy (IMRT) to the whole pelvis and to compare the results with other studies implementing a small field size of the prostate bed. METHODS: The medical records of 170 patients with high-risk prostate cancer who received SRT for biochemical recurrence following prostatectomy were reviewed...
2018: PloS One
https://www.readbyqxmd.com/read/29316026/treatment-dynamics-of-bone-targeting-agents-among-men-with-bone-metastases-from-prostate-cancer-in-the-united-states
#15
Anne M Butler, Karynsa Cetin, Rohini K Hernandez, B Diane Reams, Robert A Overman, Jung I Kim, Bradford R Hirsch, Amy P Abernethy, Alexander Liede, M Alan Brookhart
PURPOSE: To examine the dynamics of treatment with 2 bone-targeting agents (BTAs)-denosumab and zoledronic acid-among men with bone metastases from prostate cancer. METHODS: Using electronic health record data from oncology practices across the US, we identified prostate cancer patients diagnosed with bone metastasis in 2012/2013 without evidence of BTA use within 6 months prior to diagnosis. We examined the risk and predictors of BTA initiation, interruption, and re-initiation...
January 7, 2018: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29315174/oligorecurrent-nodal-prostate-cancer-long-term-results-of-an-elective-nodal-irradiation-approach
#16
Sebastien Tran, Sandra Jorcano, Teresa Falco, Giorgio Lamanna, Raymond Miralbell, Thomas Zilli
OBJECTIVES: The objective of this study was to report long-term results of elective nodal radiotherapy (ENRT) in prostate cancer (PCa) patients with oligorecurrent nodal disease after primary treatment. METHODS: Data of 53 oligorecurrent PCa patients (N1 and/or M1a) with ≤5 nodal metastases (n=108) treated with ENRT combined with androgen deprivation therapy (ADT) between 2004 and 2016 were retrospectively reviewed. Median prostate-specific antigen (PSA) and PSA doubling time (DT) were 3...
January 8, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29314097/effect-of-fak-inhibitor-vs-6063-defactinib-on-docetaxel-efficacy-in-prostate-cancer
#17
Hui-Ming Lin, Brian Y Lee, Lesley Castillo, Calan Spielman, Judith Grogan, Nicole K Yeung, James G Kench, Phillip D Stricker, Anne-Maree Haynes, Margaret M Centenera, Lisa M Butler, S Martin Shreeve, Lisa G Horvath, Roger J Daly
BACKGROUND: Docetaxel, the standard chemotherapy for metastatic castration-resistant prostate cancer (CRPC) also enhances the survival of patients with metastatic castration-sensitive prostate cancer (CSPC) when combined with androgen-deprivation therapy. Focal Adhesion Kinase (FAK) activation is a mediator of docetaxel resistance in prostate cancer cells. The aim of this study was to investigate the effect of the second generation FAK inhibitor VS-6063 on docetaxel efficacy in pre-clinical CRPC and CSPC models...
January 5, 2018: Prostate
https://www.readbyqxmd.com/read/29313098/decrease-of-bone-mineral-density-in-japanese-patients-with-non-metastatic-prostate-cancer-treated-with-androgen-deprivation-therapy
#18
Seiichi Kato, Makoto Kawase, Daiki Kato, Takashi Ishida, Masahiro Uno, Yoshinori Fujimoto, Takako Masue, Naruyasu Masue, Takashi Deguchi
The aim of this study was to conduct a cross-sectional survey of investigations related to the bone mineral density (BMD) of both non-metastatic prostate cancer (NMPC) patients who have not yet received androgen deprivation therapy (ADT) and patients receiving prolonged ADT in Japan. Japanese male patients with NMPC who received continuous ADT or who were planning to receive ADT were enrolled in this study. Lumbar spine and femoral neck BMD was measured using dual-energy X-ray absorptiometry (DEXA). To assess patient characteristics, we searched medical records and questionnaires to determine whether they had any factors that could possibly affect BMD...
January 8, 2018: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29310183/re-surrogate-end-points-for-all-cause-mortality-in-men-with-localized-unfavorable-risk-prostate-cancer-treated-with-radiation-therapy-vs-radiation-therapy-plus-androgen-deprivation-therapy-a-secondary-analysis-of-a-randomized-clinical-trial
#19
https://www.readbyqxmd.com/read/29307052/prognostic-factors-in-chinese-patients-with-prostate-cancer-receiving-primary-androgen-deprivation-therapy-validation-of-japan-cancer-of-the-prostate-risk-assessment-j-capra-score-and-impacts-of-pre-existing-obesity-and-diabetes-mellitus
#20
Meng-Bo Hu, Tian Yang, Ji-Meng Hu, Wen-Hui Zhu, Hao-Wen Jiang, Qiang Ding
PURPOSE: Our aim was to determine the prognostic factors in Chinese patients with prostate cancer receiving primary androgen deprivation therapy (PADT), validate the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score, and investigate the impacts of pre-existing obesity and diabetes mellitus (DM). METHODS: The study enrolled Chinese patients diagnosed with prostatic adenocarcinoma and treated with bilateral orchiectomy as PADT at Huashan Hospital, Fudan University (Shanghai, China), from January 2003 to December 2015...
January 6, 2018: International Journal of Clinical Oncology
keyword
keyword
58120
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"